Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to webcast for the presentation of Lime Technologies’ Interim Report, January - March 2022

Lime Technologies’ Interim Report for January - March 2022, will be published on Tuesday April 26, 2022, at 07:50 CET.The same day, at 09:30 CET; analysts, investors, media and other interested parties are invited to attend a webcast where Lime’s CEO, Nils Olsson, and CFO/Head of Investor Relations, Magnus Hansson, will comment on the published report and answer questions. The presentation will be held in English. The presentation material will be available on Lime’s website  after the webcast. How

Finnair flies to 77 destinations in winter 2022, as travel continues to recover

Finnair has updated its offering for winter 2022-2023, with a view to the Russian airspace closure. Finnair flies to ten Asian destinations, five US destinations, and 62 European destinations from its Helsinki hub during the winter. Finnair also has direct flights to the US and Thailand from Stockholm Arlanda.   “We are happy to see travel recovering at a rapid pace, and our winter network caters to the needs of both corporate and leisure travelers,” says Ole Orvér, Chief Commercial Officer, Finnair.   Finnair’s US offering comprises daily flights to New York John F Kennedy airport

The first subjects dosed successfully with no adverse events in the phase I trial of BSG005

April 19, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that there were no adverse events at all reported after the first volunteers have been dosed with the Company’s proprietary antifungal drug candidate BSG005.The Company has received the first safety review group outcome of the safety and laboratory data following this first administration of BSG005 in the phase I study in Australia. The review of the data revealed that there were no adverse events reported at all and all laboratory data were OK. This is very positive news and also promising for the next dose

Polymer Factory collaborate with University of Massachusetts Amherst

Polymer Factory Sweden AB (publ) has signed a material transfer agreement with the University of Massachusetts Amherst (UMass) for transfer of materials from its BowtieD® platform.Polymer Factory has signed a material transfer agreement with UMass for research incorporating products from Polymer Factory’s BowtieD® platform. The research focus is within oncology and immunotherapy. CTO Michael Malkoch comments: “With this agreement secured, renowned researchers from UMass will now have the opportunity to explore Polymer Factory’s dendrimer nanocarrier platform as the most sophisticated

Carbiotix certified according to ISO 9001 quality management standard

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has been certified according to the ISO 9001:2015 quality management standard. The certificate number 9001-1172 was issued on the 12th of April by Svensk Certifiering AB and covers all activities at the Company’s head office and lab, including research & development, design, packaging, marketing, sales and the distribution of IT-services. Achieving ISO 9001 certification is important as it demonstrates a high level of quality management across the Company and is demanded by many customers, especially larger companies

BioStock: Sensidose ready for expansion and IPO

Sensidose is a pharmaceutical company that sells a proprietary, non-invasive and personalized dosing system for Parkinson’s patients, who are towards the later phases of the disease. The company’s medicine and dosing system is currently marketed in Sweden, Norway and Denmark, and Sensidose aims to expand to more geographic markets. Furthermore Sensidose is developing its treatment system with a new dosing device aimed towards patients who are in an earlier stage of the disease. As Sensidose is preparing for an IPO in 2022, BioStock contacted CEO Jack Spira to find out more about the plans for

Invitation to conference call, April 26 at 14:00 pm (CEST)

Studsvik AB presents its Interim Report for the first quarter 2022 and hereby invites media and analysts to a conference call held in English on Tuesday, April 26 at 14:00 pm (CEST).   Studsvik’s Interim Report for the first quarter 2022 will be distributed at approximately 12:00 am (CEST), April 26. As of this time, the report will also be available at www.studsvik.com.   The call will be held in English, starting 14:00 pm (CEST).   Please call at least ten minutes prior to the start of the conference call to avoid delay. Event title is: Studsvik Q1 2022.

Notice of annual general meeting in Alzinova AB (publ)

The shareholders of Alzinova AB (publ) reg. no. 556861-8168 (the “Company”) are hereby summoned to attend the Annual General Meeting (the “AGM”) on 18 May 2022 at 14.00 CEST at Stenasalen in Ågrenska villan at the university of Gothenburg (address Högåsplatsen 2) in Gothenburg. Registration starts at 13.30 CEST.Right to participateShareholders that wish to participate in the AGM shall be registered in the share register maintained by Euroclear Sweden AB no later than on 10 May 2022 and shall have notified the Company of their intention to participate at the AGM no later than on 12 May

New European patent approval for Episurf Medical

The European patent office EPO has announced its intention to grant another European patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Method for designing an individually customized implant” relates to Episurf Medical’s individualised Episealer® Femoral Twin joint implant and its design process. “This patent forms a part of our overall IP protection in Europe for the company’s implant technology, and gives protection in the field of patient-specific implant design based on medical imaging”, comments Katarina Flodström, COO, Episurf Medical.

Crown Energy releases an update on South Africa Block 2B

Crown Energy AB (publ) is pleased to note today’s Press Release from Africa Energy Corp.  (“Africa Energy”) whereby Africa Energy confirms the deposit of approximately USD $20 million by Eco (Atlantic) Oil & Gas Ltd. (“Eco Atlantic”) into escrow to support its capital expenditure requirements for the Gazania-1 well after Eco Atlantic’s closing of the Azinam Group acquisition. The contracted rig is expected to mobilise from the North Sea in August to travel to South Africa. The well is expected to spud during October.’   For additional information, please see the Africa Energy´s

Epiroc wins large order for battery-electric mining equipment in South Africa

Stockholm, Sweden: Epiroc, a leading productivity partner for the mining and Infrastructure industries, has won a large order for battery-electric mining equipment from Assmang Proprietary Limited to be used at a manganese ore mine in South Africa.Assmang has ordered several of Epiroc’s battery loaders and mine trucks – the Scooptram ST14 Battery and Minetruck MT42 Battery, respectively - that will be deployed at its Black Rock underground mine in the Northern Cape Province. The order was booked in the first quarter 2022 and is valued at MSEK 120. “Epiroc is proud to support Assmang

Invitation to presentation of Sedana Medical’s interim report for the first quarter 2022

Sedana Medical AB (publ) plans to present its interim report for the first quarter 2022 in an audiocast on April 28 at 13.30 CET.According to the financial calendar, Sedana Medical plans to publish the report for the first quarter 2022 on Thursday April 28 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Johan Spetz, CFO, and Peter Sackey, CMO, as well as answer questions. Date: Thursday April 28 2022Time (CET): 13.30Link to audiocast: https://

Karo Pharma’s rights issue fully subscribed

Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction in which the distribution or release would be unlawful or require further registration measures. This press release does not constitute an offer of any securities of Karo Pharma Aktiebolag. See the section “Important information” below.The result of Karo Pharma Aktiebolag’s (“Karo Pharma”) rights issue of approximately SEK 2.5 billion (the “Rights Issue”) shows that 47,954,417

The Board of Directors resolves on a rights issue of units of approximately SEK 42.5 million, part of the issue proceeds is intended to finance further development of ALZ-201

The Board of Directors of Alzinova AB (publ) (“Alzinova” or “the Company”) has today, subject to the subsequent approval of the Annual General Meeting which is to be held on 18 May 2022, resolved on an issue of units consisting of shares and warrants of series TO3 (the “Warrants”) with pre-emption rights for the shareholders of approximately SEK 42.5 million (the “Rights Issue”), and resolved to propose that the Annual General Meeting amends the Company’s Articles of Association regarding the limits for the number of shares and the share capital. The Rights Issue is covered to approximately

NOTICE OF ANNUAL GENERAL MEETING IN SCANDINAVIAN ENVIRO SYSTEMS AB (PUBL)

The shareholders of Scandinavian Enviro Systems AB (publ), reg. no. 556605-6726 (the “Company”), are hereby given notice to the Annual General Meeting on Thursday, May 19, 2022 at 4:00 p.m. at Hotel Riverton, Stora Badhusgatan 26, in Gothenburg, Sweden. The Board of Directors has decided that the shareholders shall be able to exercise their voting rights at the Meeting also by postal voting in accordance with the regulations in the Company’s Articles of Association. The Company is also planning to give the shareholders possibility to follow the Annual General Meeting via a live

Enhertu granted Priority Review for HER2m NSCLC

19 April 2022 07:00 BST Enhertugranted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer Based on pivotal DESTINY-Lung01 results showing AstraZeneca and Daiichi Sankyo's Enhertu demonstrated a 54.9% tumour response rate If approved, Enhertu to provide patients with a much-needed targeted therapy option AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with

Concentric receives a development contract from a global OEM for a high voltage electric coolant pump in a fuel cell application

Concentric AB has received a new development contract to supply electric coolant pumps for a fuel cell application. The customer, a global truck, bus and construction OEM, will use our e-pumps for cooling the fuel cells on a range of vehicles. Fuel cells will be one of the key technology enablers for zero emissions on-highway vehicles and off-highway machines. Fuel cells give similar power density to internal combustion engines and as such will be suitable for high power and long range applications. The electric coolant pump has the following key benefits: · Enables the use of

Notice to attend the Annual General Meeting of Bricknode Holding AB (publ)

Shareholders in Bricknode Holding AB (publ), Reg. No 559083-5970, are hereby given notice of the Annual General Meeting to be held on Thursday May 19, 2022.The Board of Directors has decided that the Annual General Meeting, pursuant to temporary legislation, will be conducted without physical presence, with shareholders exercising their voting rights only by postal voting. Bricknode will arrange a digital event on Thursday, May 19, 2022, at 1.00 pm CET, where shareholders will have the opportunity to listen to senior executives and ask questions. Information about this event will be

Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2021

Stockholm, Sweden–April 19[th] 2022: Modus Therapeutics Holding AB (publ) (”Modus Therapeutics”) announces today that the company is publishing the annual report for 2021.The annual report is now available to download at the company’s website: https://www.modustx.com/investors/financial-reports.html For more information on Modus Therapeutics, please contact: John Öhd, VD, Modus Therapeutics Telefon: +46 (0) 70 766 80 97 E-post: john.ohd@modustx.com Certified Adviser Svensk Kapitalmarknadsgranskning AB Telefon: +46 11 32 30 732 E-post: ca@skmg.se *** About Modus

Cidron Romanov Limited cancels written procedure

Cidron Romanov Limited has on the date hereof given instructions to Intertrust (Sweden) AB (in its capacity as agent for the noteholders) for its SEK 2,550,000,000 & NOK 2,500,000,000 senior secured floating rate notes 2021/2026 with SEK ISIN: NO0011134413 and NOK ISIN: NO0011134405 (the "Notes"), to cancel the ongoing written procedure initiated on 30 March 2022. The Notes has been admitted to trading on Oslo Børs (the Oslo Stock Exchange) prior to the listing deadline as set out in the terms and conditions for the Notes.  For further information, please contact: Oscar Karlsson,

Africa Energy Block 2B Operations Update

VANCOUVER, BC, April 19, 2022 /CNW/ – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, is pleased to report that Eco (Atlantic) Oil & Gas Ltd. (“Eco Atlantic”) has deposited approximately US$20 million in escrow to support its capital expenditure requirements for the Gazania-1 well on Block 2B offshore South Africa after closing the acquisition of Azinam Group Limited. Garrett Soden, Africa Energy’s President and CEO, commented, “We are excited to move

ABGSC to publish Q1 2022 Interim Report on 26 April

ABG Sundal Collier (“ABGSC”) will publish its Q1 2022 figures on 26 April 2022 at 08.00 CET. The report will be available on our corporate website www.abgsc.com. Webcast presentationCEO Jonas Ström, Managing Partner Oslo Peter Straume and CFO Geir B. Olsen will present the Q1 result through a webcast at 09.00 CET followed by a Q&A session. The webcast presentation can be accessed through a web link or call-in details presented on our corporate website www.abgsc.com. For further information:Geir B. Olsen, CFO, +47 22 01 60 35 For media contacts:Petter Brunnberg, Head of

Alzinova AB interim report January – March 2022

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2022Three months, January – March 2022 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,282,156 SEK (-1,461,253 SEK). · Earnings per share amounted to -0.14 SEK (-0.09 SEK). · Equity ratio amounted to 91.4% (93.6%). Significant events during January – March 2022 · Alzinova announced in January 2022 that the company had completed work on adapting the antibody to humans and selected a main candi­date

Climeon Introduces HeatPower 300 to the Cruise Industry

Climeon AB will introduce the next generation of Climeon HeatPower, the Climeon HeatPower 300 Marine , to the cruise industry at Seatrade Cruise Global in Miami, 25-28 April 2022. The Climeon HeatPower 300 Marine is a waste heat recovery product optimized for marine conditions and designed to generate clean energy from onboard, low-temperature waste heat. HeatPower 300 Marine will assist shipowners and operators to increase their ships energy efficiency, reduce fuel consumption and decrease carbon emissions, thus achieving regulatory compliance

There are no items matching the current filter
There are no more items matching the current filter
Back to top